Orforglipron for hypertension

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 29 Apr 2025: Trial registered, NCT06948435
  2. 30 Apr 2025: Trial started, NCT06948435
  3. 30 Apr 2025: Trial started, NCT06952530
  4. 1 May 2025: Trial registered, NCT06952530

The trials

NCT06948435: A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

State
Under way
Phase
Phase 3
People
487 planned
Started
30 Apr 2025
Primary completion
Sep 2027
Arms
Orforglipron
Results
None posted
  1. 29 Apr 2025: Trial registered
  2. 30 Apr 2025: Trial started

NCT06952530: A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

State
Under way
Phase
Phase 3
People
487 planned
Started
30 Apr 2025
Primary completion
Sep 2027
Arms
Orforglipron
Results
None posted
  1. 30 Apr 2025: Trial started
  2. 1 May 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.